These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8520868)

  • 1. FDA's fraud policy and ethical concerns.
    Lepore P
    Qual Assur; 1995 Mar; 4(1):8-11. PubMed ID: 8520868
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advisory committees" critical to the FDA's product review process.
    Rados C
    FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 5. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's Quality System Inspection Technique in Ireland.
    Higgins S
    Med Device Technol; 2001; 12(1):40-1. PubMed ID: 11317865
    [No Abstract]   [Full Text] [Related]  

  • 7. The emperor is marching around buck naked.
    Noble JH
    BMJ; 2012 Jan; 344():e541. PubMed ID: 22275411
    [No Abstract]   [Full Text] [Related]  

  • 8. Assuring the integrity, accuracy, and quality of scientific information.
    Pendergast MK
    Qual Assur; 1993; 2(1-2):57-61. PubMed ID: 8156222
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioethics and applied biomaterials.
    Saha S; Saha P
    J Biomed Mater Res; 1987 Aug; 21(Suppl. A2):181-90. PubMed ID: 11649924
    [No Abstract]   [Full Text] [Related]  

  • 10. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 11. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 12. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 13. Extraordinary measures for countermeasures to terrorism: FDA's "Animal Rule".
    Hanna KE
    Hastings Cent Rep; 2002; 32(4):9. PubMed ID: 12362530
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's consideration of Codex Alimentarius standards in light of international trade agreements.
    Sikes L
    Food Drug Law J; 1998; 53(2):327-35. PubMed ID: 10346688
    [No Abstract]   [Full Text] [Related]  

  • 15. Your mission is ... academic fraud and theft are a growing problem as researchers struggle to keep to an ethical code that is never talked about. Now some of science's top names are taking up the fight to keep the profession honest.
    Cohen P
    New Sci; 1999 Jul; 162(2193):38-41. PubMed ID: 11657935
    [No Abstract]   [Full Text] [Related]  

  • 16. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 17. Off-label promotion: is FDA's final guidance on industry-supported scientific and educational programs enforceable?
    Bass IS; Kalb PE; Berenson BA
    Food Drug Law J; 1998; 53(2):193-212. PubMed ID: 10346681
    [No Abstract]   [Full Text] [Related]  

  • 18. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA's reaction to corporate compliance audits.
    Shroff AP
    Food Drug Law J; 1996; 51(2):221-3. PubMed ID: 11820199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.